Xuan-Fu Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xuan-Fu Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chuanyong Guo
Department of Gastroenterology, Shanghai Tenth People's Hospital Tongji University School of Medicine Shanghai China
2 shared publications Bing-Fang Wang
Department of Gastroenterology, Kunshan Hospital, Jiangsu University, Jiangsu Province, Kunshan 215300, China
1 shared publicationChuan-Gao Xie
Department of Gastroenterology, the Second Hospital, Zhejiang University
1 shared publication- Chun-Yan Wang
Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province Health Sciences Institute of China Medical University Shenyang China
1 shared publication Hong-Lang Hu
Department of Gastroenterology, the Tenth Hospital, Tongji University
1 shared publicationJian-Ye Wu
Department of Gastroenterology, Third People's Hospital of Changzhou, Jiangsu Province, Changzhou 213001, China
1 shared publication
Latest Publications
- Open Access
- 9 April 2012
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2012, 1-8
Modified Sequential Therapy Regimen versus Conventional Triple Therapy forHelicobacter pyloriEradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study
Objective. Antimicrobial resistance has decreased eradication rates for Helicobacter pylori infection worldwide. To observe the effect of eradicating Helicobacter pylori (H. pylori) and the treatment of duodenal ulcer by 2 kinds of modified sequential therapy through comparing with that of 10-day standard triple therapy. Methods. A total of 210 patients who were confirmed in duodenal ulcer active or heal period by gastroscopy and H. pylori positive confirmed by rapid urease test, serum anti-H. pylori antibody (ELASE), or histological examination enrolled in the study. All the patients were randomly divided into three groups: group A (70 cases) and group B (70 cases) were provided 10-day modified sequential therapy; group C (70 cases) was provided 10-day standard triple therapy. Patients of group A received 20mg of Esomeprazole, 500mg of Clarithromycin for the first 5 days, followed by 20mg of Esomeprazole, 500mg of Clarithromycin, and 1000mg of Amoxicillin for the remaining 5 days. Group B received 20mg of Esomeprazole, 1000mg of Amoxicillin for the first 5 days, followed by 20mg of Esomeprazole, 500mg of Clarithromycin, and 1000mg of Amoxicillin for the remaining 5 days. Group C received 20mg of Esomeprazole, 500mg of Clarithromycin, and 1000mg of Amoxicillin for standard 10-day therapy. All drugs were given twice daily. H. pylori eradication rate was checked four to eight weeks after taking the medicine by using a 13C urea breath test. In the first, second, third, seventh, twenty-first, thirty-fifth days respectively, the symptoms of patients such as epigastric gnawing, burning pain, and acidity were evaluated simultaneously. Results. Overall, 210 patients accomplished all therapy schemes, 9 case patients were excluded. The examination result indicated that the H. pylori eradication rate of each group was as follows: group A 92.5% (62/67), group B 86.8% (59/68), and group C 78.8% (52/66). The H. pylori eradication rate of group A was slightly higher than group B (𝑃<0.05) and both of them were obviously higher than group C (𝑃0.05). Conclusions. All the three therapy schemes could alleviate symptoms of duodenal ulcer patients in China efficiently. But as far as eradicating H. pylori is concerned, the modified sequential therapy was better than standard triple therapy, especially the therapy scheme used in group A.
- 9 April 2012
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2012, 1-8
Open AccessModified Sequential Therapy Regimen versus Conventional Triple Therapy forHelicobacter pyloriEradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study
Objective. Antimicrobial resistance has decreased eradication rates for Helicobacter pylori infection worldwide. To observe the effect of eradicating Helicobacter pylori (H. pylori) and the treatment of duodenal ulcer by 2 kinds of modified sequential therapy through comparing with that of 10-day standard triple therapy. Methods. A total of 210 patients who were confirmed in duodenal ulcer active or heal period by gastroscopy and H. pylori positive confirmed by rapid urease test, serum anti-H. pylori antibody (ELASE), or histological examination enrolled in the study. All the patients were randomly divided into three groups: group A (70 cases) and group B (70 cases) were provided 10-day modified sequential therapy; group C (70 cases) was provided 10-day standard triple therapy. Patients of group A received 20mg of Esomeprazole, 500mg of Clarithromycin for the first 5 days, followed by 20mg of Esomeprazole, 500mg of Clarithromycin, and 1000mg of Amoxicillin for the remaining 5 days. Group B received 20mg of Esomeprazole, 1000mg of Amoxicillin for the first 5 days, followed by 20mg of Esomeprazole, 500mg of Clarithromycin, and 1000mg of Amoxicillin for the remaining 5 days. Group C received 20mg of Esomeprazole, 500mg of Clarithromycin, and 1000mg of Amoxicillin for standard 10-day therapy. All drugs were given twice daily. H. pylori eradication rate was checked four to eight weeks after taking the medicine by using a 13C urea breath test. In the first, second, third, seventh, twenty-first, thirty-fifth days respectively, the symptoms of patients such as epigastric gnawing, burning pain, and acidity were evaluated simultaneously. Results. Overall, 210 patients accomplished all therapy schemes, 9 case patients were excluded. The examination result indicated that the H. pylori eradication rate of each group was as follows: group A 92.5% (62/67), group B 86.8% (59/68), and group C 78.8% (52/66). The H. pylori eradication rate of group A was slightly higher than group B (𝑃<0.05) and both of them were obviously higher than group C (𝑃0.05). Conclusions. All the three therapy schemes could alleviate symptoms of duodenal ulcer patients in China efficiently. But as far as eradicating H. pylori is concerned, the modified sequential therapy was better than standard triple therapy, especially the therapy scheme used in group A.
- Open Access
- 1 January 2008
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 215 (2) , 149-157
Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo
Cyclooxygenase-2 (COX-2), a prostaglandin synthetase, is involved in development of certain tumors. We therefore analyzed COX-2 expression in pancreatic cancer tissues (53 samples) and Panc-1 human pancreatic cancer cells by immunohistochemistry, RT-PCR and western-blotting analyses. Also, immunohistochemistry of proliferating cell nuclear antigen (PCNA) was performed. We found expression of COX-2 was dramatically upregulated in 36 of 53 cases (67.9%) and the expression of COX-2 was associated with the diameter (> 3 cm) of the tumors (p < 0.05), but not with the age, gender, tumor location, differentiation, lymph-node metastases and TNM stage. The positivity rate of PCNA expression in the pancreatic cancer cells of the COX-2 positive group (32.88 ± 13.26%) was significantly higher than that in the COX-2 negative group (24.56 ± 11.51%) (p < 0.05). Then we investigated the effect of selective inhibitors of COX-2 (NS398 and celecoxib) on proliferation of Panc-1 cells by 3-(4,5 dimethyl-2-thiazolyl)-2.5-diphenyl-2H-tetrazolium bromide (MTT) assay. Either NS398 or celecoxib suppressed proliferation of Panc-1 cells dose-dependently in vitro. Furthermore, Panc-1 cells were implanted into nude mice, and celecoxib was administrated orally with feed. The volume of the tumor xenografted into nude mice was decreased by 51.6% in the celecoxib group (p < 0.01). In conclusion, the increased expression of COX-2 may be responsible for rapid proliferation of pancreatic cancer, and specific inhibition of COX-2 suppresses proliferation of Panc-1 cells in vitro and in nude mice. The selective inhibitor of COX-2 may be an effectual agent for pancreatic cancer chemoprevention.
- 1 January 2008
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 215 (2) , 149-157
Open AccessSelective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo
Cyclooxygenase-2 (COX-2), a prostaglandin synthetase, is involved in development of certain tumors. We therefore analyzed COX-2 expression in pancreatic cancer tissues (53 samples) and Panc-1 human pancreatic cancer cells by immunohistochemistry, RT-PCR and western-blotting analyses. Also, immunohistochemistry of proliferating cell nuclear antigen (PCNA) was performed. We found expression of COX-2 was dramatically upregulated in 36 of 53 cases (67.9%) and the expression of COX-2 was associated with the diameter (> 3 cm) of the tumors (p < 0.05), but not with the age, gender, tumor location, differentiation, lymph-node metastases and TNM stage. The positivity rate of PCNA expression in the pancreatic cancer cells of the COX-2 positive group (32.88 ± 13.26%) was significantly higher than that in the COX-2 negative group (24.56 ± 11.51%) (p < 0.05). Then we investigated the effect of selective inhibitors of COX-2 (NS398 and celecoxib) on proliferation of Panc-1 cells by 3-(4,5 dimethyl-2-thiazolyl)-2.5-diphenyl-2H-tetrazolium bromide (MTT) assay. Either NS398 or celecoxib suppressed proliferation of Panc-1 cells dose-dependently in vitro. Furthermore, Panc-1 cells were implanted into nude mice, and celecoxib was administrated orally with feed. The volume of the tumor xenografted into nude mice was decreased by 51.6% in the celecoxib group (p < 0.01). In conclusion, the increased expression of COX-2 may be responsible for rapid proliferation of pancreatic cancer, and specific inhibition of COX-2 suppresses proliferation of Panc-1 cells in vitro and in nude mice. The selective inhibitor of COX-2 may be an effectual agent for pancreatic cancer chemoprevention.